DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on July 9, 2007; DOI: 10.1124/dmd.107.015644


0090-9556/07/3510-1766-1780$20.00
DMD 35:1766-1780, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.015644v1
35/10/1766    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Buck, S. S.
Right arrow Articles by Gilissen, R. A. H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Buck, S. S.
Right arrow Articles by Gilissen, R. A. H. J.

Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs

Stefan S. De Buck, Vikash K. Sinha, Luca A. Fenu, Marjoleen J. Nijsen, Claire E. Mackie, and Ron A. H. J. Gilissen

Johnson & Johnson Pharmaceutical Research and Development, Discovery ADME-Tox Department, Beerse, Belgium

The aim of this study was to evaluate different physiologically based modeling strategies for the prediction of human pharmacokinetics. Plasma profiles after intravenous and oral dosing were simulated for 26 clinically tested drugs. Two mechanism-based predictions of human tissue-to-plasma partitioning (Ptp) from physicochemical input (method Vd1) were evaluated for their ability to describe human volume of distribution at steady state (Vss). This method was compared with a strategy that combined predicted and experimentally determined in vivo rat Ptp data (method Vd2). Best Vss predictions were obtained using method Vd2, providing that rat Ptp input was corrected for interspecies differences in plasma protein binding (84% within 2-fold). Vss predictions from physicochemical input alone were poor (32% within 2-fold). Total body clearance (CL) was predicted as the sum of scaled rat renal clearance and hepatic clearance projected from in vitro metabolism data. Best CL predictions were obtained by disregarding both blood and microsomal or hepatocyte binding (method CL2, 74% within 2-fold), whereas strong bias was seen using both blood and microsomal or hepatocyte binding (method CL1, 53% within 2-fold). The physiologically based pharmacokinetics (PBPK) model, which combined methods Vd2 and CL2 yielded the most accurate predictions of in vivo terminal half-life (69% within 2-fold). The Gastroplus advanced compartmental absorption and transit model was used to construct an absorption-disposition model and provided accurate predictions of area under the plasma concentration-time profile, oral apparent volume of distribution, and maximum plasma concentration after oral dosing, with 74%, 70%, and 65% within 2-fold, respectively. This evaluation demonstrates that PBPK models can lead to reasonable predictions of human pharmacokinetics.


Address correspondence to: Stefan S. De Buck, Ablynx nv, Technologiepark 4, B-9052 Ghent/Zwijnaarde, Belgium. E-mail: stefan.debuck{at}ablynx.com







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.